Revolution Medicines RVMDW Institutional Ownership

Updated Oct 28, 2026

Revolution Medicines, Inc. (NASDAQ:RVMDW) was reported as a holding by 22 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Total holdings of Revolution Medicines shares rose 0.29% from Q1 2026, and the number of holders fell 4.35% from Q2 2025.
• Looking at the 22 holders of RVMDW individually, 6 added to their positions, 3 reduced their stakes and 13 left their positions unchanged.
• The aggregate institutional position in Revolution Medicines was 10.09Mn shares at the end of Q2 2026, up 28.86K from the prior quarter and up 2.02Mn from a year earlier.
• As of June 30, 2026, LMR Partners LLP held the largest stake in Revolution Medicines with 5.07Mn shares.
• Among holders that already owned Revolution Medicines, the biggest buyers in Q2 2026 were LMR Partners LLP (+1.23Mn shares), CSS LLC (+60.86K shares) and UBS Group AG (+1.57K shares).
• Holders that trimmed the most shares of Revolution Medicines in Q2 2026 while keeping a position were Sculptor Capital LP (-249.15K shares), Wolverine Asset Management LLC (-16.15K shares) and Osaic Holdings, Inc. (-30 shares).
• Business Quant data shows the 10 biggest positions in Revolution Medicines as of Q2 2026 were held by LMR Partners LLP (5.07Mn shares), D. E. Shaw & Co., Inc. (1.58Mn shares), Sculptor Capital LP (709.67K shares), T. Rowe Price Associates Inc (579.55K shares), Caption Management, LLC (517.68K shares), Adage Capital Partners GP, L.L.C. (500K shares), Perceptive Advisors LLC (250K shares), Bleichroeder LP (200K shares), Wolverine Asset Management LLC (154.54K shares) and Farallon Capital Management, L.L.C. (120.08K shares).